Silence Therapeutics (NASDAQ:SLN) Releases Earnings Results, Misses Expectations By $0.13 EPS

Silence Therapeutics (NASDAQ:SLN) released its quarterly earnings data on Monday. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.13), FiscalAI reports. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%.

Silence Therapeutics Stock Performance

Silence Therapeutics stock opened at $11.95 on Monday. The company has a market cap of $564.52 million, a P/E ratio of -7.52 and a beta of 1.39. Silence Therapeutics has a 1-year low of $4.19 and a 1-year high of $12.31. The company has a fifty day simple moving average of $9.31 and a 200 day simple moving average of $7.18.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on SLN shares. Cantor Fitzgerald started coverage on Silence Therapeutics in a research note on Wednesday, June 24th. They set an “overweight” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Wednesday, June 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Silence Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $75.00.

Hedge Funds Weigh In On Silence Therapeutics

Large investors have recently modified their holdings of the business. XTX Topco Ltd bought a new position in shares of Silence Therapeutics in the 4th quarter valued at about $71,000. Citadel Advisors LLC bought a new stake in Silence Therapeutics during the third quarter worth about $112,000. Massar Capital Management LP acquired a new position in Silence Therapeutics during the second quarter valued at approximately $115,000. ADAR1 Capital Management LLC boosted its position in Silence Therapeutics by 26.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock valued at $144,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in Silence Therapeutics in the fourth quarter valued at approximately $177,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.